MX2008011112A - Formulaciones farmaceuticas de latrunculina. - Google Patents

Formulaciones farmaceuticas de latrunculina.

Info

Publication number
MX2008011112A
MX2008011112A MX2008011112A MX2008011112A MX2008011112A MX 2008011112 A MX2008011112 A MX 2008011112A MX 2008011112 A MX2008011112 A MX 2008011112A MX 2008011112 A MX2008011112 A MX 2008011112A MX 2008011112 A MX2008011112 A MX 2008011112A
Authority
MX
Mexico
Prior art keywords
formulation
latrunculin
present
amount
formulations
Prior art date
Application number
MX2008011112A
Other languages
English (en)
Spanish (es)
Inventor
Ramesh Krishnamoorthy
Leo A Trevino
Richard M Evans
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of MX2008011112A publication Critical patent/MX2008011112A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2008011112A 2006-03-02 2007-03-02 Formulaciones farmaceuticas de latrunculina. MX2008011112A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77927306P 2006-03-02 2006-03-02
US11/680,893 US7785624B2 (en) 2006-03-02 2007-03-01 Pharmaceutical latrunculin formulations
PCT/US2007/063171 WO2007103782A2 (en) 2006-03-02 2007-03-02 Pharmaceutical latrunculin formulations

Publications (1)

Publication Number Publication Date
MX2008011112A true MX2008011112A (es) 2008-09-08

Family

ID=38475717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011112A MX2008011112A (es) 2006-03-02 2007-03-02 Formulaciones farmaceuticas de latrunculina.

Country Status (10)

Country Link
US (2) US7785624B2 (https=)
EP (1) EP1993563A4 (https=)
JP (1) JP2009528390A (https=)
KR (1) KR20080098636A (https=)
AU (1) AU2007223378A1 (https=)
BR (1) BRPI0708483A2 (https=)
CA (1) CA2644198A1 (https=)
MX (1) MX2008011112A (https=)
RU (1) RU2434633C2 (https=)
WO (1) WO2007103782A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014240A2 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of California Novel bioactive small molecules derived from sea sponges
EP3397651B1 (en) 2015-12-29 2020-05-06 Galderma S.A. Carbohydrate crosslinker
JP7386080B2 (ja) * 2016-08-02 2023-11-24 アンバー アイピー リミテッド 安定なイブプロフェン注射製剤用組成物
US20220047719A1 (en) * 2020-08-17 2022-02-17 Northwestern University Enhancing subcutaneous injection and target tissue accumulation of nanoparticles via co-administration with macropinocytosis inhibitory nanoparticles (minp)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2052950A1 (en) 1990-10-10 1992-04-11 David P. Evitts Aqueous ophthalmic microemulsions of tepoxalin
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US6586425B2 (en) 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JP3677421B2 (ja) * 1999-12-27 2005-08-03 扶桑薬品工業株式会社 涙液分泌促進組成物
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
CN101160315A (zh) * 2005-03-25 2008-04-09 印斯拜尔药品股份有限公司 细胞骨架的活性化合物，组合物及用途

Also Published As

Publication number Publication date
WO2007103782A3 (en) 2008-03-20
JP2009528390A (ja) 2009-08-06
EP1993563A4 (en) 2009-05-20
US7785624B2 (en) 2010-08-31
RU2434633C2 (ru) 2011-11-27
US20100305175A1 (en) 2010-12-02
KR20080098636A (ko) 2008-11-11
EP1993563A2 (en) 2008-11-26
RU2008139113A (ru) 2010-04-10
CA2644198A1 (en) 2007-09-13
WO2007103782A2 (en) 2007-09-13
AU2007223378A1 (en) 2007-09-13
US20070225343A1 (en) 2007-09-27
BRPI0708483A2 (pt) 2011-05-31

Similar Documents

Publication Publication Date Title
CL2009000573A1 (es) Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo.
ES2095566T3 (es) Suspension farmaceutica acuosa para agentes activos farmaceuticos.
NZ610068A (en) Compositions comprising povidone-iodine
WO2009028495A1 (ja) 真菌性皮膚炎用剤
MX368377B (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
AU2001278696A1 (en) Aqueous pharmaceutical compositions
DK1294371T4 (da) Fedtsyrer med middellange kæder, hvilke fedtsyrer kan anvendes som antimikrobielle midler
ES2193658T3 (es) Procedimiento para la preparacion de formulaciones acuosas para uso oftalmico.
EP2452562A3 (en) Composition for preventing plant diseases and method for preventing the diseases
MX2008011112A (es) Formulaciones farmaceuticas de latrunculina.
WO2006131737A3 (en) Method and composition for treating inflammatory disorders
TW200511941A (en) Method of reducing unpleasant taste and/or unpleasant odor
MX2012012846A (es) Composicion oftalmica.
MX336114B (es) Produccion, formulacion, y usos de formulaciones liquidas estables de proteina harpin.
WO2006026083A3 (en) Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
AR052252A1 (es) Formulaciones topicas de nepafenac
ATE492620T1 (de) Antimikrobielle handwaschformulierungen
MX2009013062A (es) Derivados de 3´4´,5-trimetoxi flavona como estimulante de secrecion de mucosa, metodo de los mismos, y composicion farmaceutica que comprende los mismos.
AU2003259789A8 (en) High concentration surfactant compositions and methods
MXPA03000223A (es) Derivados de pirrolidina como inhibidores de la enzima conversor de endotelina.
WO2008102349A3 (en) Terbinafine formulation for iontophoresis
MX2025007492A (es) Compuestos lipidicos y composiciones de nanoparticulas lipidicas
AU2002329042A1 (en) Ophthalmic composition containing n-acetylcysteine for the treat ment of dry-eye syndrome

Legal Events

Date Code Title Description
FG Grant or registration